{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:56:54Z","timestamp":1790996214036,"version":"4.1.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006319","name":"Centre National pour la Recherche Scientifique et Technique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtauto.2025.100288","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T02:33:18Z","timestamp":1745029998000},"page":"100288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The role of soluble CD40L in autoimmune diseases"],"prefix":"10.1016","volume":"10","author":[{"given":"Meryem","family":"Mabrouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hicham","family":"Wahnou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahye","family":"Merhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haissam","family":"Abou-Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadila","family":"Guessous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-9106","authenticated-orcid":false,"given":"Younes","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtauto.2025.100288_bib1","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/eji.1830221226","article-title":"Cloning of TRAP, a ligand for CD40 on human T cells","volume":"22","author":"Graf","year":"1992","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib2","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3389\/fimmu.2017.01484","article-title":"CD40L expression allows CD8+ T cells to promote their own expansion and differentiation through dendritic cells","volume":"8","author":"Tay","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1600-0609.2004.00342.x","article-title":"Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L","volume":"74","author":"Nagasawa","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jtauto.2025.100288_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jtauto.2025.100288_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1160\/TH09-01-0029","article-title":"The multi-functionality of CD40L and its receptor CD40 in atherosclerosis","volume":"102","author":"Lievens","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jtauto.2025.100288_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"Van Kooten","year":"2000","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib7","doi-asserted-by":"crossref","first-page":"36083","DOI":"10.1074\/jbc.M113.506220","article-title":"CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner","volume":"288","author":"Yacoub","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtauto.2025.100288_bib8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1538-7836.2010.03837.x","article-title":"CD40 ligand shedding is regulated by interaction between matrix metalloproteinase\u20102 and platelet integrin \u03b1IIb\u03b23","volume":"8","author":"Choi","year":"2010","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.jtauto.2025.100288_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jtauto.2025.100288_bib10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(97)80078-7","article-title":"Functions of CD40 on B cells, dendritic cells and other cells","volume":"9","author":"van Kooten","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/01.ATV.0000122853.99978.b1","article-title":"CD154\/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction","volume":"24","author":"Wagner","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib12","first-page":"53","article-title":"De novo mutation causing X-linked hyper-IgM syndrome: a family study in Taiwan","volume":"23","author":"Ma","year":"2005","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/biof.62","article-title":"CD40\/CD40L signaling and its implication in health and disease","volume":"35","author":"Chatzigeorgiou","year":"2009","journal-title":"Biofactors"},{"key":"10.1016\/j.jtauto.2025.100288_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jtauto.2025.100288_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4155\/tde.11.60","article-title":"Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics","volume":"2","author":"Chittasupho","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jtauto.2025.100288_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2567.2000.00074.x","article-title":"Fortifying B cells with CD154: an engaging tale of many hues","volume":"100","author":"Gordon","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.jtauto.2025.100288_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/361539a0","article-title":"Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM","volume":"361","author":"Korth\u00e4uer","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2025.100288_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1074-7613(00)80578-6","article-title":"Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody-secreting cells in germinal centers","volume":"8","author":"Randall","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.jtauto.2025.100288_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0092-8674(94)90335-2","article-title":"Signals and signs for lymphocyte responses","volume":"76","author":"Janeway","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jtauto.2025.100288_bib22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1084\/jem.180.4.1263","article-title":"Activation of human dendritic cells through CD40 cross-linking","volume":"180","author":"Caux","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib23","doi-asserted-by":"crossref","first-page":"12597","DOI":"10.1128\/JVI.79.19.12597-12601.2005","article-title":"Human immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells","volume":"79","author":"Del","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jtauto.2025.100288_bib24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.184.2.747","article-title":"Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation","volume":"184","author":"Cella","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib25","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/378617a0","article-title":"Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand","volume":"378","author":"Grewal","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2025.100288_bib26","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.4049\/jimmunol.162.8.4373","article-title":"Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease","volume":"162","author":"Buhlmann","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib27","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/31002","article-title":"T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jtauto.2025.100288_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1161\/ATVBAHA.115.307074","article-title":"Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes","volume":"36","author":"Gerdes","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002459","article-title":"Platelets guide leukocytes to their sites of extravasation","volume":"14","author":"Zuchtriegel","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jacc.2017.11.055","article-title":"Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis","volume":"71","author":"Seijkens","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jtauto.2025.100288_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1172\/JCI118855","article-title":"Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes","volume":"98","author":"Koshy","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100288_bib32","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1172\/JCI118643","article-title":"Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production","volume":"97","author":"Desai-Mehta","year":"1996","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100288_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.168.1.9","article-title":"Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease","volume":"168","author":"Higuchi","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1172\/JCI7014","article-title":"The soluble CD40 ligand sCD154 in systemic lupus erythematosus","volume":"104","author":"Kato","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100288_bib35","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/1529-0131(199905)42:5<871::AID-ANR5>3.0.CO;2-J","article-title":"Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera","volume":"42","author":"Vakkalanka","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib36","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0006-291X(75)90508-2","article-title":"Atomic models for the polypeptide backbones of myohemerythrin and hemerythrin","volume":"66","author":"Hendrickson","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jtauto.2025.100288_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0006-2944(75)90147-7","article-title":"Formate assay in body fluids: application in methanol poisoning","volume":"13","author":"Makar","year":"1975","journal-title":"Biochem. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/09537104.2011.595850","article-title":"Platelet-derived microparticles cause CD154-dependent activation of dendritic cells","volume":"23","author":"Nomura","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.jtauto.2025.100288_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/039463200301600307","article-title":"CD40 ligand-dependent maturation of human monocyte-derived dendritic cells by activated platelets","volume":"16","author":"Kaneider","year":"2003","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jtauto.2025.100288_bib40","first-page":"825","article-title":"[Platelet-associated CD154: a new interface in haemostasis and in the inflammatory reaction]","volume":"21","author":"Delmas","year":"2005","journal-title":"Med. Sci."},{"key":"10.1016\/j.jtauto.2025.100288_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jlb.63.4.418","article-title":"The role of CD40\/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells","volume":"63","author":"Mackey","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/eji.201444941","article-title":"Interaction of CD154 with different receptors and its role in bidirectional signals","volume":"45","author":"Alturaihi","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1084\/jem.180.1.157","article-title":"gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory","volume":"180","author":"Foy","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib44","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4049\/jimmunol.157.7.3159","article-title":"Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response","volume":"157","author":"Early","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib45","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.4049\/jimmunol.160.5.2158","article-title":"Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function","volume":"160","author":"Kalled","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.40792","article-title":"Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-\u03b1","volume":"71","author":"Mathian","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100288_bib47","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/art.38573","article-title":"Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare","volume":"66","author":"Munroe","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100288_bib48","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.4049\/jimmunol.154.3.1470","article-title":"Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis","volume":"154","author":"Mohan","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/art.10929","article-title":"Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus","volume":"48","author":"Wang","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/art.11230","article-title":"Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis","volume":"48","author":"Quezada","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib51","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib52","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.10681","article-title":"Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Kalunian","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jtauto.2025.100288_bib54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.23.021704.115707","article-title":"Immunology of multiple sclerosis","volume":"23","author":"Sospedra","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib55","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.4049\/jimmunol.161.3.1104","article-title":"Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo","volume":"161","author":"Issazadeh","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib56","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1126\/science.273.5283.1864","article-title":"Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis","volume":"273","author":"Grewal","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jtauto.2025.100288_bib57","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1073\/pnas.93.6.2499","article-title":"CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis","volume":"93","author":"Gerritse","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jtauto.2025.100288_bib58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1172\/JCI5388","article-title":"Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis","volume":"103","author":"Howard","year":"1999","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100288_bib59","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.4049\/jimmunol.166.3.1547","article-title":"Autoimmune intervention by CD154 blockade prevents T cell retention and effector function in the target organ","volume":"166","author":"Howard","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s001090050145","article-title":"CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation","volume":"75","author":"Samoilova","year":"1997","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.jtauto.2025.100288_bib61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0165-5728(99)00152-6","article-title":"CD40 engagement stimulates IL-12 p70 production by human microglial cells: basis for Th1 polarization in the CNS","volume":"102","author":"Becher","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib62","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4049\/jimmunol.176.3.1402","article-title":"CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation","volume":"176","author":"Ponomarev","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib63","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-5728(99)00053-3","article-title":"Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis","volume":"97","author":"Tan","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib64","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.193.8.967","article-title":"The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system","volume":"193","author":"Becher","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib65","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","article-title":"Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"305","author":"Masuda","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib66","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.imbio.2017.10.001","article-title":"Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis","volume":"223","author":"de J Guerrero-Garc\u00eda","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.jtauto.2025.100288_bib67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3748\/wjg.14.338","article-title":"Inflammatory bowel disease: genetic and epidemiologic considerations","volume":"14","author":"Cho","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jtauto.2025.100288_bib68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12272-020-01296-1","article-title":"IL-1 and CD40\/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets","volume":"44","author":"Anka Idrissi","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.jtauto.2025.100288_bib69","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.4049\/jimmunol.176.4.2617","article-title":"TNF-alpha blockade down-regulates the CD40\/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease","volume":"176","author":"Danese","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib70","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3389\/fimmu.2015.00529","article-title":"The contribution of CD40\/cd40l Axis in inflammatory bowel disease: an update","volume":"6","author":"Senhaji","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib71","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.4049\/jimmunol.164.11.6005","article-title":"Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions","volume":"164","author":"Liu","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib72","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.183.2.693","article-title":"Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion","volume":"183","author":"Stuber","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2005.02526.x","article-title":"Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease","volume":"22","author":"Kasran","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jtauto.2025.100288_bib74","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2003-07-2367","article-title":"Platelet-associated CD154 in immune thrombocytopenic purpura","volume":"105","author":"Solanilla","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2025.100288_bib75","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren\u2019s syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100288_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/sji.12121","article-title":"Upregulation of membrane\u2010bound CD 40L on CD 4 + T cells in women with primary sj\u00f6gren\u2019s syndrome","volume":"79","author":"Belkhir","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1600-065X.2008.00648.x","article-title":"The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis","volume":"223","author":"Noss","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jtauto.2025.100288_bib78","first-page":"1035","article-title":"Ligation of CD40 induced tumor necrosis factor-alpha in rheumatoid arthritis: a novel mechanism of activation of synoviocytes","volume":"26","author":"Harigai","year":"1999","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100288_bib79","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1172\/JCI119781","article-title":"Functional CD40 ligand is expressed by T cells in rheumatoid arthritis","volume":"100","author":"MacDonald","year":"1997","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jtauto.2025.100288_bib80","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/1529-0131(199909)42:9<1917::AID-ANR18>3.0.CO;2-2","article-title":"Differential regulation of rheumatoid synovial cell interleukin-12 production by tumor necrosis factor alpha and CD40 signals","volume":"42","author":"Kitagawa","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jtauto.2025.100288_bib82","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/art.20106","article-title":"Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts","volume":"50","author":"Cho","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib83","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/art.20133","article-title":"Augmented production of chemokines by the interaction of type II collagen-reactive T cells with rheumatoid synovial fibroblasts","volume":"50","author":"Min","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib84","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1126\/science.7689748","article-title":"Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40","volume":"261","author":"Durie","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jtauto.2025.100288_bib85","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1002\/1529-0131(200011)43:11<2571::AID-ANR26>3.0.CO;2-4","article-title":"The role of CD40 ligand and tumor necrosis factor alpha signaling in the transgenic K\/BxN mouse model of rheumatoid arthritis","volume":"43","author":"Kyburz","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jtauto.2025.100288_bib86","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease","volume":"106","author":"Andr\u00e9","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jtauto.2025.100288_bib87","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.175.4.1091","article-title":"Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help)","volume":"175","author":"Lederman","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib88","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1073\/pnas.94.16.8789","article-title":"CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates","volume":"94","author":"Kirk","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jtauto.2025.100288_bib89","first-page":"95","article-title":"Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus","volume":"28","author":"Davis","year":"2001","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jtauto.2025.100288_bib90","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtauto.2025.100288_bib91","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2008.07039.x","article-title":"The effect of anti-CD40 ligand in immune thrombocytopenic purpura","volume":"141","author":"Patel","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jtauto.2025.100288_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","article-title":"Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges","volume":"647","author":"Law","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jtauto.2025.100288_bib93","first-page":"725","article-title":"IDEC-131. IDEC\/Eisai","volume":"3","author":"Dumont","year":"2002","journal-title":"Curr. Opin. Invest. Drugs"},{"key":"10.1016\/j.jtauto.2025.100288_bib94","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.TP.0000116392.72152.75","article-title":"Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model1","volume":"77","author":"Kanmaz","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jtauto.2025.100288_bib95","first-page":"717","article-title":"Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody","volume":"77","author":"Schuler","year":"2004","journal-title":"cynomolgus monkey renal allotransplantation1: Transplantation"},{"key":"10.1016\/j.jtauto.2025.100288_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar6584","article-title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity","volume":"11","author":"Karnell","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/annrheumdis-2019-eular.5529","article-title":"FRI0195 efficacy and safety of dapirolizumab pegol (dzp) in patients with moderately to severely active systemic lupus erythematosus (SLE): a randomised, placebo (PBO)-CONTROLLED study","volume":"78","author":"Furie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100288_bib98","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/bph.14897","article-title":"The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys","volume":"177","author":"Nicholson","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jtauto.2025.100288_bib99","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/ajt.14197","article-title":"Fc-silent anti-cd154 domain antibody effectively prevents nonhuman primate renal allograft rejection","volume":"17","author":"Kim","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jtauto.2025.100288_bib100","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1160\/TH04-12-0774","article-title":"The role of CD40 in CD40L- and antibody-mediated platelet activation","volume":"93","author":"Langer","year":"2005","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jtauto.2025.100288_bib101","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jtauto.2025.100288_bib102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nm0302-247","article-title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism","volume":"8","author":"Andr\u00e9","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtauto.2025.100288_bib103","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jtauto.2025.100288_bib104","unstructured":"Clowse M, Isenberg D, Merrill J, D\u00f6rner T, Petri M, Vital E, et al. Dapirolizumab pegol demonstrated significant improvement in systemic lupus erythematosus disease activityEfficacy and Safety Results of a Phase 3 Trial n.D."},{"key":"10.1016\/j.jtauto.2025.100288_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/OA-24-00040","article-title":"CD40 ligand blockade for prevention of graft-versus-host disease","author":"Khimani","year":"2025","journal-title":"JCO Oncology Advances"},{"key":"10.1016\/j.jtauto.2025.100288_bib106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0006-291X(75)90482-9","article-title":"Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution","volume":"66","author":"Bose","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jtauto.2025.100288_bib107","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1073\/pnas.1400419111","article-title":"Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance","volume":"111","author":"Chatzigeorgiou","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909025000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:17:27Z","timestamp":1762633047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909025000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":107,"alternative-id":["S2589909025000231"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100288","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of soluble CD40L in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2025.100288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100288"}}